What is the translation of " DEGLUDEK INZULINA " in English?

• insulin degludec

Examples of using Degludek inzulina in Croatian and their translations into English

Procijenjena razlika, doza degludek inzulina.
Estimated difference, insulin degludec dose.

Poluvijek degludek inzulina iznosi približno 25 sati, a poluvijek liraglutida približno 13 sati.
The half-life of insulin degludec is approximately 25 hours and the half-life of liraglutide is approximately 13 hours.

Jedan uložak(3 ml) sadrži 300 jedinica(U) degludek inzulina.
Each cartridge(3 mL) contains 300 units(U) of insulin degludec.

Afinitet degludek inzulina za albumine u serumu odgovara vezivanju na proteine plazme od> 99% u humanoj plazmi.
The affinity of insulin degludec to serum albumin corresponds to a plasma protein binding of> 99% in human plasma.

Jedan ml otopine sadrži 100 jedinica(U) degludek inzulina.
Each mL of solution contains 100 units(U) of insulin degludec.

Ne postoje razlike u farmakokinetici degludek inzulina između zdravih ispitanika i bolesnika s oštećenjem jetre.
There is no difference in the pharmacokinetics of insulin degludec between healthy subjects and patients with hepatic impairment.

Jedna napunjena brizgalica(3 ml) sadrži 300 jedinica(U) degludek inzulina.
Each pre-filled pen(3 mL) contains 300 units(U) of insulin degludec.

Ml otopine sadrži 100 jedinica degludek inzulina* i 3, 6 mg liraglutida.
ML solution contains 100 units insulin degludec* and 3.6 mg liraglutide.

Razgradnja degludek inzulina i aspart inzulina slična je razgradnji humanog inzulina; svi nastali metaboliti su neaktivni.
Degradation of insulin degludec and insulin aspart is similar to that of human insulin; all metabolites formed are inactive.

Jedan uložak sadrži 300 jedinica degludek inzulina u 3 ml otopine.
One cartridge contains 300 units of insulin degludec in 3 mL solution.

Monomeri degludek inzulina postupno se odvajaju od multiheksamera, čime dolazi do sporog i neprestanog ulaska degludek inzulina u cirkulaciju.
Insulin degludec monomers gradually separate from the multi-hexamers thus resulting in a slow and continuous delivery of insulin degludec into the circulation.

Jedna napunjena brizgalica sadrži 300 jedinica degludek inzulina u 3 ml otopine.
One pre-filled pen contains 300 units of insulin degludec in 3 mL solution.

Nisu provedena ispitivanja s kombinacijom degludek inzulina/liraglutida s ciljem procjene kancerogenosti, mutagenosti ili poremećaja plodnosti.
No studies have been conducted with the insulin degludec/liraglutide combination to evaluate carcinogenesis, mutagenesis or impairment of fertility.

Odmjernog koraka do najviše 50 odmjernih koraka 50 jedinica degludek inzulina+ 1, 8 mg liraglutida.
Dose step to a maximum of 50 dose steps 50 units insulin degludec+ 1.8 mg liraglutide.

Xultophy je kombinirani lijek koji se sastoji od degludek inzulina i liraglutida s komplementarnim mehanizmima djelovanja radi poboljšanja regulacije glikemije.
Xultophy is a combination product consisting of insulin degludec and liraglutide having complementary mechanisms of action to improve glycaemic control.

Preporučena početna doza lijeka Xultophy je 10 odmjernih koraka 10 jedinica degludek inzulina i 0, 36 mg liraglutida.
The recommended starting dose of Xultophy is 10 dose steps 10 units insulin degludec and 0.36 mg liraglutide.

Jedna(1) jedinica(U) degludek inzulina odgovara 1 internacionalnoj jedinici(IU) humanog inzulina, 1 jedinici glargin inzulina ili 1 jedinici detemir inzulina..
One(1) unit(U) of insulin degludec corresponds to 1 international unit(IU) of human insulin, 1 unit of insulin glargine or 1 unit of insulin detemir.

Jedan odmjerni korak sadrži 1 jedinicu degludek inzulina i 0, 036 mg liraglutida.
One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide.

Sveukupno, na farmakokinetiku degludek inzulina i liraglutida nije klinički značajno utjecala njihova primjena u obliku lijeka Xultophy u usporedbi s primjenom zasebnih injekcija degludek inzulina i liraglutida.
Overall, the pharmacokinetics of insulin degludec and liraglutide were not affected in a clinically relevant manner when administered as Xultophy compared with independent injections of insulin degludec and liraglutide.

Nema kliničkog iskustva s primjenom lijeka Xultophy, degludek inzulina ili liraglutida u trudnica.
There is no clinical experience with use of Xultophy, insulin degludec or liraglutide in pregnant women.

Sljedeći podaci odražavaju farmakokinetička svojstva lijeka Xultophy, osim ako nije navedeno da se prikazani podaci odnose na primjenu samog degludek inzulina ili samog liraglutida.
The following reflects the pharmacokinetic properties of Xultophy unless stated that the presented data is from administration of insulin degludec or liraglutide alone.

Omjer mitogenog i metaboličkog potencijala degludek inzulina, usporediv je s onim za humani inzulin..
The ratio of mitogenic relative to metabolic potency for insulin degludec is comparable to that of human insulin..

Ryzodeg 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici 70% degludek inzulina/ 30% aspart inzulina..
Ryzodeg 100 units/mL solution for injection in pre-filled pen 70% insulin degludec/ 30% insulin aspart.

Omjer mitogenog i metaboličkog potencijala degludek inzulina nepromijenjen je u usporedbi s onim za humani inzulin..
The ratio of mitogenic relative to metabolic potency for insulin degludec is unchanged compared to human insulin..

Ukupna izloženost degludek inzulinu nakon primjene lijeka Xultophy bila je ekvivalentna onoj nakon primjene samog degludek inzulina, dok je Cmax bio 12% viši.
The overall exposure of insulin degludec was equivalent following administration of Xultophy versus insulin degludec alone while the Cmax was higher by 12.

Jedan ml otopine sadrži ukupno 100 jedinica(U) degludek inzulina/aspart inzulina u omjeru 70/30.
Each mL of solution contains a total of 100 units(U) insulin degludec/insulin aspart in the ratio 70/30.

Najveća dnevna doza lijeka Xultophy je 50 odmjernih koraka 50 jedinica degludek inzulina i 1, 8 mg liraglutida.
The maximum daily dose of Xultophy is 50 dose steps 50 units of insulin degludec and 1.8 mg of liraglutide.

Početna doza lijeka Xultophy bila je 16 odmjernih koraka(16 jedinica degludek inzulina i 0, 6 mg liraglutida), a titrirala se dvaput tjedno prema Tablici 2.
The starting dose of Xultophy was 16 dose steps(16 units insulin degludec and 0.6 mg liraglutide) and the dose was titrated twice weekly according to Table 2.

Tvari dodane lijeku Ryzodeg mogu izazvati razgradnju degludek inzulina i/ili aspart inzulina..
Substances added to Ryzodeg may cause degradation of insulin degludec and/or insulin aspart.

Farmakokinetički profil lijeka Xultophy u skladu je s doziranjem jednom dnevno, a koncentracija degludek inzulina i liraglutida u stanju dinamičke ravnoteže dostiže se nakon 2-3 dana svakodnevne primjene.
The pharmacokinetic profile of Xultophy is consistent with once daily dosing and steady state concentration of insulin degludec and liraglutide is reached after 2-3 days of daily administration.